A promising response of refractory uterine leiomyosarcoma to pembrolizumab and temozolomide combination therapy

Document Type

Article

Publication Date

1-1-2024

Abstract

Uterine leiomyosarcomas (ULMS) are a rare cause of uterine malignancy. Due to their aggressive nature, resistance to standard therapy and high rates of recurrence, they are associated with a very poor prognosis, irrespective of their stage at diagnosis. A 68-year-old female, Chinese patient was diagnosed with Stage IVB uterine leiomyosarcoma with lung metastasis. Disease progression occurred after fourth-line treatment and the patient was commenced on pembrolizumab and temozolomide combination therapy. At the time of writing, our patient has experienced partial response to treatment with minimal adverse effects at cycle 7 of Pembrolizumab in combination with Temozolomide. © 2024 The Authors

Keywords

Combination therapy, Immunotherapy, Pembrolizumab, Refractory uterine leiomyosarcoma, Temzolomide, Uterine malignancy

Publication Title

Gynecologic Oncology Reports

Divisions

oncology

Volume

51

Publisher

Elsevier B.V.

This document is currently not available here.

Share

COinS